Reasons for consideration, page-32

Still amazed as some punters comments on this thread. Straight from Dr T's mouth- "We have nevertheless formed a view that partnering options are better considered once Neuren has met with the FDA". Obviously it is clear from those comments Dr T was waiting on the P3 specifics before finalising a deal, post FDA meeting i believe we are in a stronger negotiating positions. Now i agree until an announcement is made this is all speculation however those saying we might have a cap raise and go it alone are kidding themselves. We have an orphan drug here, i highly doubt we have been in discussions with one party. We would have multiple parties interested and in discussions which in my view will provide a fair market value for what we have. Is like a house auction, we'd have 4-5 bidders who will push the price to market rather than the 1 bidder who tries to low ball us.